Halozyme Therapeutics, Inc. Stock News

Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor ​against Merck , ordering the drugmaker to halt the ‌manufacture and sale of injectable Keytruda in eight European markets.

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from ma...

Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets. "We are pleased to...

SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").

SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management.